South Korea
· Delayed Price · Currency is KRW PanGen Biotech Statistics
Total Valuation
PanGen Biotech has a market cap or net worth of KRW 72.75 billion. The enterprise value is 69.04 billion.
| Market Cap | 72.75B |
| Enterprise Value | 69.04B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
PanGen Biotech has 12.90 million shares outstanding. The number of shares has increased by 3.61% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 12.90M |
| Shares Change (YoY) | +3.61% |
| Shares Change (QoQ) | -4.54% |
| Owned by Insiders (%) | 4.25% |
| Owned by Institutions (%) | n/a |
| Float | 6.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.54 |
| PB Ratio | 3.57 |
| P/TBV Ratio | 4.22 |
| P/FCF Ratio | 171.89 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 48.34, with an EV/FCF ratio of 163.14.
| EV / Earnings | -115.28 |
| EV / Sales | 5.03 |
| EV / EBITDA | 48.34 |
| EV / EBIT | n/a |
| EV / FCF | 163.14 |
Financial Position
The company has a current ratio of 3.30, with a Debt / Equity ratio of 0.13.
| Current Ratio | 3.30 |
| Quick Ratio | 1.63 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 1.60 |
| Debt / FCF | 5.39 |
| Interest Coverage | -0.20 |
Financial Efficiency
Return on equity (ROE) is -3.65% and return on invested capital (ROIC) is -0.23%.
| Return on Equity (ROE) | -3.65% |
| Return on Assets (ROA) | -0.18% |
| Return on Capital (ROIC) | -0.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.17 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.89% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -13.89% |
| 50-Day Moving Average | 5,462.40 |
| 200-Day Moving Average | 5,250.90 |
| Relative Strength Index (RSI) | 53.32 |
| Average Volume (20 Days) | 62,088 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PanGen Biotech had revenue of KRW 13.72 billion and -598.90 million in losses. Loss per share was -57.42.
| Revenue | 13.72B |
| Gross Profit | 5.29B |
| Operating Income | -68.12M |
| Pretax Income | -551.47M |
| Net Income | -598.90M |
| EBITDA | 1.43B |
| EBIT | -68.12M |
| Loss Per Share | -57.42 |
Balance Sheet
The company has 5.99 billion in cash and 2.28 billion in debt, giving a net cash position of 3.71 billion or 287.29 per share.
| Cash & Cash Equivalents | 5.99B |
| Total Debt | 2.28B |
| Net Cash | 3.71B |
| Net Cash Per Share | 287.29 |
| Equity (Book Value) | 18.02B |
| Book Value Per Share | 1,578.58 |
| Working Capital | 10.62B |
Cash Flow
In the last 12 months, operating cash flow was 725.45 million and capital expenditures -302.24 million, giving a free cash flow of 423.21 million.
| Operating Cash Flow | 725.45M |
| Capital Expenditures | -302.24M |
| Free Cash Flow | 423.21M |
| FCF Per Share | 32.81 |
Margins
Gross margin is 38.54%, with operating and profit margins of -0.50% and -4.36%.
| Gross Margin | 38.54% |
| Operating Margin | -0.50% |
| Pretax Margin | -4.02% |
| Profit Margin | -4.36% |
| EBITDA Margin | 10.41% |
| EBIT Margin | -0.50% |
| FCF Margin | 3.08% |
Dividends & Yields
PanGen Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.61% |
| Shareholder Yield | -3.61% |
| Earnings Yield | -1.02% |
| FCF Yield | 0.58% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
PanGen Biotech has an Altman Z-Score of 3.25.
| Altman Z-Score | 3.25 |
| Piotroski F-Score | n/a |